<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863954</url>
  </required_header>
  <id_info>
    <org_study_id>08165-01</org_study_id>
    <nct_id>NCT00863954</nct_id>
  </id_info>
  <brief_title>Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes</brief_title>
  <official_title>A Controlled Pilot Study of the Application of Magnetic Fields Using the Resonator in Adjunctive Management of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pico-tesla Magnetic Therapies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>pico-tesla Magnetic Therapies, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if using a device called the Resonator, that puts out a&#xD;
      very low electromagnetic field, effects blood glucose and A1c levels in people with Type 2&#xD;
      Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to determine whether application of magnetic fields&#xD;
      generated by the Resonator result in statistically significant reductions in finger stick&#xD;
      blood glucose levels, serum glucose and hemoglobin A1c levels. The study will also&#xD;
      investigate any induced changes in serum lipids and liver function tests as indirect markers&#xD;
      of insulin resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in blood glucose and A1c levels at endpoint compared to start</measure>
    <time_frame>Start point, 3 months and 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Output A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Output B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Output C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Output D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Output E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Output F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resonator Device</intervention_name>
    <description>comparison of different parameter settings of electromagnetic fields using the Resonator Device</description>
    <arm_group_label>Output A</arm_group_label>
    <arm_group_label>Output B</arm_group_label>
    <arm_group_label>Output C</arm_group_label>
    <arm_group_label>Output D</arm_group_label>
    <arm_group_label>Output E</arm_group_label>
    <arm_group_label>Output F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of Type II Diabetes Mellitus with A1c level above the upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Subject currently performs routine finger stick blood sugar testing&#xD;
&#xD;
          -  Subject is ambulatory&#xD;
&#xD;
          -  None or stable medication regimen without significant side effects for at least 6&#xD;
             months, willingness and ability to maintain the stable medication regimen throughout&#xD;
             the course of the study.&#xD;
&#xD;
          -  Hemoglobin A1c levels within a 0.8% range of patient mean A1c level for the last two&#xD;
             documented determinations, that must be within 2 years of the baseline testing date.&#xD;
&#xD;
          -  Willingness to test finger stick blood sugars according to protocol.&#xD;
&#xD;
          -  Willingness to have lab test blood draws performed according to protocol&#xD;
&#xD;
          -  Willingness to maintain stable diet and activity regimen for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Willing and able to abstain from partaking in any non-essential existing or new&#xD;
             treatments to improve serum blood sugar levels.&#xD;
&#xD;
          -  Adequate contraceptive measures for female subjects&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Any ethnic group&#xD;
&#xD;
          -  Between 21 and 80 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Change in medical regimen within 6 months prior to initiation of study&#xD;
&#xD;
          -  Any signs of Type I diabetes&#xD;
&#xD;
          -  Active infectious process within 3 weeks of study initiation causing wide fluctuations&#xD;
             in finger stick blood sugar level.&#xD;
&#xD;
          -  Change in BMI of greater than 6% within a 6 month period prior to study initiation&#xD;
&#xD;
          -  Any planned revascularization procedure&#xD;
&#xD;
          -  Symptomatic congestive heart failure&#xD;
&#xD;
          -  Leg or foot ulceration or open wounds&#xD;
&#xD;
          -  Gangrene&#xD;
&#xD;
          -  History of intermittent claudication&#xD;
&#xD;
          -  Hemodialysis&#xD;
&#xD;
          -  Currently being treated for malignancy&#xD;
&#xD;
          -  Currently being treated with oral or intravenous catabolic steroids.&#xD;
&#xD;
          -  Reported consumption of more than 14 alcoholic drinks per week.&#xD;
&#xD;
          -  Pregnant, breast feeding,or planning pregnancy prior to the end of participation.&#xD;
&#xD;
          -  Developmental disability or cognitive impairment that would make it difficult for the&#xD;
             subject to partake in the clinical study, including adequate comprehension of the&#xD;
             informed consent form and ability to record the necessary measurements.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Uncontrolled atrial fibrillation or other uncontrolled arrythmias, e.g. tachycardia,&#xD;
             bradycardia&#xD;
&#xD;
          -  Uncontrolled seizure disorder&#xD;
&#xD;
          -  Uncontrolled, unstable, or untreated medical conditions which may significantly impact&#xD;
             the subjects health or ability to complete the entire study, in the opinion of the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>pico-tesla Magnetic Therapies</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>December 14, 2010</last_update_submitted>
  <last_update_submitted_qc>December 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Allen S. Braswell CEO, pico-tesla Magnetic Therapies, LLC</name_title>
    <organization>pico-tesla Magnetic Therapies, LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

